200 related articles for article (PubMed ID: 12513682)
1. ECVAM-ICCVAM: prospects for future collaboration.
Schechtman LM; Stokes WS
Altern Lab Anim; 2002 Dec; 30 Suppl 2():227-36. PubMed ID: 12513682
[TBL] [Abstract][Full Text] [Related]
2. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): a review of the ICCVAM test method evaluation process and current international collaborations with the European Centre for the Validation of Alternative Methods (ECVAM).
Stokes WS; Schechtman LM; Hill RN
Altern Lab Anim; 2002 Dec; 30 Suppl 2():23-32. PubMed ID: 12513648
[TBL] [Abstract][Full Text] [Related]
3. A new path forward: the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
Casey W; Jacobs A; Maull E; Matheson J; Clarke C; Lowit A
J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):170-3. PubMed ID: 25836963
[TBL] [Abstract][Full Text] [Related]
4. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods.
Schechtman LM
ILAR J; 2002; 43 Suppl():S85-94. PubMed ID: 12388858
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from validation of in vitro toxicity test: from failure to acceptance into regulatory practice.
Spielmann H; Liebsch M
Toxicol In Vitro; 2001; 15(4-5):585-90. PubMed ID: 11566595
[TBL] [Abstract][Full Text] [Related]
6. Future improvements: replacement in vitro methods.
Balls M
ILAR J; 2002; 43 Suppl():S69-73. PubMed ID: 12388855
[TBL] [Abstract][Full Text] [Related]
7. FRAME Annual Lecture. International co-operation: an essential requirement for replacing animal toxicity tests.
Spielmann H
Altern Lab Anim; 2001; 29(6):637-46; discussion 647-8. PubMed ID: 11709040
[TBL] [Abstract][Full Text] [Related]
8. [Validation and regulatory acceptance of alternative methods for toxicity evaluation].
Ohno Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2004; (122):1-9. PubMed ID: 15940895
[TBL] [Abstract][Full Text] [Related]
9. The principles of validation and the ECVAM validation process.
Worth AP; Balls M
Altern Lab Anim; 2002 Dec; 30 Suppl 2():15-21. PubMed ID: 12513647
[TBL] [Abstract][Full Text] [Related]
10. Dialogue and collaboration: a personal view on laboratory animal welfare developments in general, and on ECVAM's first decade in particular.
Koëter HB
Altern Lab Anim; 2002 Dec; 30 Suppl 2():207-10. PubMed ID: 12513676
[TBL] [Abstract][Full Text] [Related]
11. Collaboration between ZEBET, FRAME, and ECVAM: FRAME's contribution to establishing the Three Rs in Europe.
Spielmann H
Altern Lab Anim; 2009 Dec; 37 Suppl 2():23-7. PubMed ID: 20105007
[TBL] [Abstract][Full Text] [Related]
12. The contributions of the European cosmetics industry to the development of alternatives to animal testing: dialogue with ECVAM and future challenges.
de Silva O;
Altern Lab Anim; 2002 Dec; 30 Suppl 2():189-93. PubMed ID: 12513672
[TBL] [Abstract][Full Text] [Related]
13. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.
Corvi R; Ahr HJ; Albertini S; Blakey DH; Clerici L; Coecke S; Douglas GR; Gribaldo L; Groten JP; Haase B; Hamernik K; Hartung T; Inoue T; Indans I; Maurici D; Orphanides G; Rembges D; Sansone SA; Snape JR; Toda E; Tong W; van Delft JH; Weis B; Schechtman LM
Environ Health Perspect; 2006 Mar; 114(3):420-9. PubMed ID: 16507466
[TBL] [Abstract][Full Text] [Related]
14. The FDA's regulatory role in the ICCVAM process.
Schechtman LM; Stokes WS
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():663-8. PubMed ID: 23581155
[TBL] [Abstract][Full Text] [Related]
15. The ECVAM workshops: a critical assessment of their impact on the development, validation and acceptance of alternative methods.
Combes RD
Altern Lab Anim; 2002 Dec; 30 Suppl 2():151-65. PubMed ID: 12513668
[TBL] [Abstract][Full Text] [Related]
16. Report of the EPAA-ECVAM workshop on the validation of Integrated Testing Strategies (ITS).
Kinsner-Ovaskainen A; Maxwell G; Kreysa J; Barroso J; Adriaens E; Alépée N; Berg N; Bremer S; Coecke S; Comenges JZ; Corvi R; Casati S; Dal Negro G; Marrec-Fairley M; Griesinger C; Halder M; Heisler E; Hirmann D; Kleensang A; Kopp-Schneider A; Lapenna S; Munn S; Prieto P; Schechtman L; Schultz T; Vidal JM; Worth A; Zuang V
Altern Lab Anim; 2012 Jul; 40(3):175-81. PubMed ID: 22943518
[TBL] [Abstract][Full Text] [Related]
17. Dialogue and collaboration with ECVAM: the view of the EFPIA.
Garthoff B
Altern Lab Anim; 2002 Dec; 30 Suppl 2():195-8. PubMed ID: 12513673
[TBL] [Abstract][Full Text] [Related]
18. ICCVAM evaluation of the murine local lymph node assay. The ICCVAM review process.
Sailstad DM; Hattan D; Hill RN; Stokes WS
Regul Toxicol Pharmacol; 2001 Dec; 34(3):249-57. PubMed ID: 11754529
[TBL] [Abstract][Full Text] [Related]
19. Validation and regulatory acceptance of alternatives.
Hill RN; Stokes WS
Camb Q Healthc Ethics; 1999; 8(1):73-9. PubMed ID: 9924621
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
